MyMD Pharmaceuticals, Inc. (MYMD)
MyMD Pharmaceuticals, Inc.
855 North Wolfe Street
Suite 601
Baltimore, MD 21205
United States
(856) 848-8698
https://www.mymd.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 6
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Christopher C. Chapman Jr., M.D. | President, Chief Medical Officer & Director | 665.76k | N/D | 1953 |
| Mr. Ian Rhodes CPA | Interim Chief Financial Officer | 162k | N/D | 1973 |
| Dr. Jenna Brager M.S., Ph.D., R.N. | Executive Vice President of Drug Development | N/D | N/D | N/D |
Descripción
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immunometabolic system and its pro-inflammatory cytokines to treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Gestión corporativa
La calificación ISS Governance QuickScore de MyMD Pharmaceuticals, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
